City
Epaper

Studies debate over effectiveness of hydroxychloroquine

By IANS | Published: January 18, 2022 2:27 PM

New Delhi, Jan 18 Once touted as a cure for Covid, hydroxychloroquine (HCQ), the anti-malaria drug, is renewing ...

Open in App

New Delhi, Jan 18 Once touted as a cure for Covid, hydroxychloroquine (HCQ), the anti-malaria drug, is renewing interest as a potential treatment for the infectious disease and particularly the new fast spreading Omicron variant.

Two recent studies, not peer reviewed yet, have debated over whether HCQ is effective against Covid and Omicron. While one claims to be effective against Omicron, the other recommends against its use in Covid patients.

The first study, led by researchers from the University of Glasgow, looks at how antibodies from vaccines block Omicron from entering cells.

The researchers claim that Omicron may have changed the way it enters cells: from cell surface to via endosomes.

Since HCQ is a drug that accumulates in endosomes and makes it less acidic, it cuts Covid virus' ability to enter cells. Thus HCQ could act as an antiviral, the researchers claimed.

However, the new study did not test HCQ's effect on Omicron.

In the second study, a team of researchers Johns Hopkins Bloomberg School of Public Health, and Universities of Utah, Colorado, and Vanderbilt, among others, conducted a meta-analysis of US-based randomised clinical trials (RCTs).

The researchers analysed eight RCTs in 770 hospitalised Covid patients and compared HCQ or chloroquine (CQ) and control treatment.

The results did not show evidence of a benefit of HCQ/CQ.

"This study supports the consensus that hydroxychloroquine/chloroquine should not be used to treat hospitalised patients with Covid-19," the researchers wrote in the study.

HCQ is an anti-malaria medication more commonly used to manage the symptoms of rheumatoid arthritis and autoimmune conditions such as lupus.

In the beginning of the pandemic, the US Food and Drug Administration (FDA) had provided emergency use authorisation (EUA) for the use of HCQ and CQ in the treatment of hospitalised Covid patients.

However, most retrospective-observational studies of HCQ/CQ in hospitalised Covid patients provide no evidence supporting the efficacy of this treatment.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: University Of GlasgowJohns hopkins bloomberg school of public health
Open in App

Related Stories

Football"Form they are in now is great," says Scotland's former goalkeeper David Marshall

TechnologyResearchers reveal how blood biomarkers, genomics predict common disease risk

HealthCommon infections linked to poor cognitive performance in older adults: Study

HealthStudy reveals people with HIV, hepatitis C develop high risk of heart attack as they age

HealthHealthy lifestyle may reduce dementia risk in diabetic patients

National Realted Stories

NationalPak connection detected in Ahmedabad school bomb threat case

NationalKarnataka Shocker: Man Beheads SSLC Student in Kodagu for Rejecting Marriage Proposal; Accused on Run

NationalPraveen Nettaru Murder Case: NIA Arrests Key Accused in BJP Activist Death Case

NationalAndhra Assembly polls: Will NTR's son Balayya hold on to TDP fortress Hindupur?

NationalBengaluru Rains: Flight Services Disrupted Due to Heavy Downpour at Kempegowda International Airport